# Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects

> **NCT03927391** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 57 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03927391
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-30
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927391, "Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03927391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*